NALOXONE HYDROCHLORIDE

Post-LOE

naloxone hydrochloride

Viatris (2)

ANDAINJECTIONINJECTABLE

Approved

Mar 2014

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

NALOXONE HYDROCHLORIDE (naloxone hydrochloride) by Viatris (2) is clinical pharmacology when naloxone hydrochloride is administered intravenously, the onset of action is generally apparent within 2 minutes. Approved for depression. First approved in 2014.

Drug data last refreshed Yesterday

Mechanism of Action

CLINICAL PHARMACOLOGY When naloxone hydrochloride is administered intravenously, the onset of action is generally apparent within 2 minutes. The onset of action is slightly less rapid when it is administered subcutaneously or intramuscularly. The duration of action is dependent upon the dose and…

Worked on NALOXONE HYDROCHLORIDE at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

NALOXONE HYDROCHLORIDE

Mechanism of Action

Indications (1)